Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 728 participants.

Also called NCT01294436

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 728 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01294436
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01294436. Allocation not applicable; no masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2012-09 (actual). Results posted on 2013-09-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus
Condition
Type2 Diabetes
Condition
High Blood Sugar
Intervention (Drug)
Dapagliflozin
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct01294436
Content hash
d85ebb33124034592d3db826a0d6879a21a74e9d723cd552e455c138b24f03ac